Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by biggdoggon Jul 03, 2024 4:07pm
119 Views
Post# 36116982

EU & ESG

EU & ESGBased on the new regulations in the EU, companies are getting backed into a corner to comply to all the regulations on ESG. https://plana.earth/academy/eu-esg-regulations
If you are a big pharma manufacturing company in Europe, (12 of the top 15 drug exporters are in EU), would you not look at Voyageur ESG carbon capture, and buy them out just so you can continue to operate under the tightening ESG reguations? The value of Voy ESG is big, and has not been factored into anything they are doing. Well niether has the FC project, HC licenses, $2.6M contract, etc etc. Whitenorth is right, time to pivot out of the tsxv. 
If you have a verified sustainable product, in the EU, it goes to the top of the bid list. The Canadian government is also pushing this ESG onto sustainable products to rise to the top of provincial healthcare bids. 
<< Previous
Bullboard Posts
Next >>